<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114445">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082067</url>
  </required_header>
  <id_info>
    <org_study_id>IOGPGC05-14</org_study_id>
    <nct_id>NCT02082067</nct_id>
  </id_info>
  <brief_title>Total Knee Prosthesis With Continuous Block of Adductor Canal and Outcome</brief_title>
  <official_title>Total Knee Arthroplasty &amp; Outcome: A Prospective Randomized Comparison Between Adductor Canal Block and Femoral Nerve Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Gaetano Pini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Gaetano Pini</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate the effects of the adductor canal block on the early and
      medium term ( 1 month) rehabilitation compared to the continuous femoral block commonly used
      in the knee prosthesis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Up and Go test</measure>
    <time_frame>5th  postoperative day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Knee functional evaluation at 5th postoperative day. &quot;up and go&quot; test: time need to get up from a chair, walk for 3 meters, and come back to seat down on the chair</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS score</measure>
    <time_frame>up to  POD5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of VAS static and VAS dynamic during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine request</measure>
    <time_frame>up to POD5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Opioids consumption will be recorded throughout postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of motion</measure>
    <time_frame>5th postoperative day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physiotherapist measures the maximum active/passive range of motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falling risk</measure>
    <time_frame>5th postoperative day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of falling risk with Berg Balance Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps strength</measure>
    <time_frame>5th postoperative day</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluate muscle strength with an isometric force dynamometer to measure the force produced during a maximum voluntary isometric contraction in a lying position by the knee flex to 90Â°.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adductor canal</intervention_name>
    <description>Perinervous catheter (stimulong sono- Pajunk, Germany)  will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.</description>
    <arm_group_label>Adductor canal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femoral</intervention_name>
    <description>Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.</description>
    <arm_group_label>Femoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal Anesthesia</intervention_name>
    <description>Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.</description>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local anesthetic infusion</intervention_name>
    <description>Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.</description>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous analgesia</intervention_name>
    <description>Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.</description>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0,75%</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine 0,5%</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine 0,125%</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac 30mg</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stimulong sono, Pajunk, Germany</intervention_name>
    <arm_group_label>Adductor canal</arm_group_label>
    <arm_group_label>Femoral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing total knee arthroplasty

        Exclusion Criteria:

          -  diabetes

          -  neurological disorders

          -  coagulation disorders

          -  rheumatoid arthritis

          -  chronic opioids therapy

          -  allergy to local anesthetic
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Cappelleri, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Gaetano Pini</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianluca Cappelleri, M.D.</last_name>
    <phone>+390258296297</phone>
    <email>gianluca.cappelleri@gpini.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto ortopedico Gaetano Pini</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Cappelleri, M.D.</last_name>
      <phone>+390258296297</phone>
      <email>gianluca.cappelleri@gpini.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Gaetano Pini</investigator_affiliation>
    <investigator_full_name>Gianluca Cappelleri</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
